Stock analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a note issued to investors on Tuesday. The firm set a “hold” rating on the stock.
TherapeuticsMD Stock Performance
TXMD stock opened at $1.75 on Tuesday. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $4.35. The company’s fifty day simple moving average is $1.89 and its 200 day simple moving average is $2.09.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million for the quarter.
Hedge Funds Weigh In On TherapeuticsMD
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Recommended Stories
- Five stocks we like better than TherapeuticsMD
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- How Technical Indicators Can Help You Find Oversold StocksĀ
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.